ASCO 2017- Daratumumab in combination with KRd in patients with newly diagnosed multiple myeloma
Description: Background: DARA in combination with established standard of care regimens prolongs PFS, deepens responses, and demonstrates a favorable safety profile in relapsed or refractory multiple myeloma (MM). The tolerability and efficacy of DARA-KRd in newly diagnosed MM pts was examined.
Conclusions: The addition of DARA to KRd was well tolerated; the overall safety profile was consistent with that previously reported for KRd, with no additional toxicity observed with the addition of DARA. Deep and durable responses were observed. These data support further investigation of DARA-KRd as a frontline treatment regimen. Updated data will be presented based on longer follow up.
Author(s): Andrzej J. Jakubowiak, Ajai Chari, Sagar Lonial, Brendan M. Weiss, Raymond L. Comenzo, Kaida Wu, Nushmia Z. Khokhar, Jianping Wang, Parul Doshi, Saad Zafar Usmani